AstraZeneca

Glaxo replaces ViiV Healthcare chief as executive shuffle continues The executive exodus at GlaxoSmithKline is continuing—and so is the rise of women to the company’s top ranks. The British pharma giant announced that Dominique Limet, head of HIV unit ViiV Healthcare, would step down at the end of March 2017—the sam...

Bayer Partners with DelSiTech to Develop Innovative Drug Delivery Technology for Ophthalmology Bayer has partnered with a Finnish drug delivery and drug developmental company,DelSiTechLtd., through a Collaboration and Technology Licence Agreement. The agreement gives Bayer’s compounds a worldwide application of DelS...

Collaboration between Sygnis AG and ECACC for licensing and distribution of Caco-2 cell line Sygnis AG enters into a collaboration agreement with ECACC to significantly expand Sygnis' Caco-2 business. Under the collaboration, ECACC will organize that companies obtain the license for the use of the Caco-2 cell line f...

Sun Pharma forms distribution partnership with Mitsubishi Tanabe in Japan In a recent strategic move, Sun Pharma formed a distribution alliance with Mitsubishi Tanabe Pharma Corporation in Japan for the total of 14 prescription brands which were acquired from Novartis for $293m. The brands are Parlodel, Lamisil, Nit...

AstraZeneca has got good results in the clinical trial for its next-generation asthma medication and could be available to patients by the end of next year. The drug, Benralizumab, is a new biological treatment for people with severe asthma, and works by targeting eosinophils that cause inflammation in the lungs of ...

NATCO Pharma surges 7% post successful Establishment Inspection Report for Chennai Plant NATCO pharma has reached a new high of Rs. 703 on the National Stock Exchange (NSE) as the drug maker revealed the successful Establishment Inspection Report (EIR) for Chennai Plant. The U.S. Food and Drug Administration (FDA) h...

Antibody-Drug Conjugates-A Big Boom! Therapeutics developed to create innovative medicines based on the use of new and improved antibodies is the next generation cure for the treatment of various diseases. In past decade, the antibody drug conjugates have emerged out as the active areas of many biopharmaceutical ...

264 Antibody-Drug Conjugates in Pipeline!!!! Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. Billions of dollars are spent on the chemotherapy treatments annually. The ongoing research on this therapy will replace the ch...